Navigation Links
InspireMD Announce the Completion of Enrollment for the MAGICAL Trial (MGuard(TM) in Acute Myocardial Infarction) at EuroPCR '09. Results Will be Presented May 21st by Dr. Dariusz Dudek at the InspireMD Cocktail Reception Debate Chaired by Prof. Martin Le
Date:5/21/2009

BARCELONA, Spain, May 20 /PRNewswire/ -- InspireMD, Ltd. announced today the completion of enrolment for the MAGICAL trial (MGuard(TM) in Acute Myocardial). The trial was designed to confirm the clinical feasibility, safety and performance of MGuard when used during Primary PCI in STEMI patients.

The MAGICAL trial is a multicenter, prospective, single arm, 60 patients study (Principal investigator: Dr. Dariusz Dudek, Jagiellonian University, Krakow, Poland). Primary end-points are incidence of complete ST segment resolution measured 60 minutes post procedure and incidence of TIMI 3 flow after PCI. Main secondary endpoints are myocardial blush grade and MACE (major adverse cardiac events) at discharge, 30 days and 6 months.

"I am very pleased and excited we reached this milestone" said Dr. Dariusz Dudek, the MAGICAL Study Chief Investigator, from Jagiellonian University in Krakow. "From the data collected so far, primary PCI for STEMI patients using MGuardTM seems highly safe and effective".

To date, TIMI flow 3 is 91%, MBG 3 (Myocardial Blush Grade) is 74%, Complete ST Resolution is 63%. MACE at discharge is 0% and 30 days MACE to date is 0% as well.

"This important milestone is getting us closer to confirm MGuard's important role in the treatment of acute MI patients, by providing a comprehensive solution to the distal embolization threat" said Eli Bar, CTO and VP R&D at InspireMD. "So far, the MAGICAL Trial results are confirming what we had experienced in cath-labs around the world; that the MGuardTM performs well and delivers extra safety for the patients".

A presentation of the updated results of the MAGICAL trial by Dr. Dariusz Dudek will be given at the InspireMD Cocktail Reception, May 21st at 18:30 at the Hilton Diagonal Mar, next to the EuroPCR conference CCIB Conference center. The Cocktail Reception and Debate: "What is the Best Strategy in Acute MI?" will be chaired by the world renowned opinion leader, Martin Leon MD.

About MGuard(TM) Coronary

MGuard(TM) presents a novel combination of a coronary stent merged with an embolic protection. The embolic protection is comprised of an ultra-thin polymer mesh sleeve that wraps the stent. The protective sleeve is composed of a micron-level-fiber which is knit in order to ensure flexibility while retaining the strength characteristics of the fiber material. The sleeve is designed to expand seamlessly when the stent is deployed, without effecting the structural integrity of the stent. The MGuard(TM) coronary stent provides permanent embolic protection, without complicating deliverability. Reduced injury to the vessel as a result of diffused stent pressure is a benefit of the sleeve which may lead to lower risk of restenosis. MGuard(TM) is CE Mark approved.

The MGuard(TM) Coronary's innovative concept has enjoyed an enthusiastic welcome from leading interventional cardiologists around the world.

About InspireMD

InspireMD Ltd. is an innovative medical device company focusing on the development and commercialization of its proprietary stent system technology, MGuard(TM). The company intends to apply its technology to develop products used in interventional cardiology and other vascular procedures. InspireMD's mission is to utilize its proprietary technology to make its products the industry standard for stents and to provide a superior solution to the key clinical issues of current stenting: restenosis, embolic showers, and late thrombosis.

In addition to providing embolic protection and minimizing arterial injury, this promising technology can be an effective and uniform drug delivery mechanism with the help of the novel micron-level net for next generation drug eluting stents. InspireMD intends to pursue applications of this technology both for bare metal and drug eluting stents in coronary, carotid and peripheral artery procedures.

    For further information visit:http://www.inspire-md.com

    Contact:
    Jonina Ohayon
    Marketing Director
    Tel +972-52-5791120
    jonina@inspire-md.com


'/>"/>
SOURCE InspireMD
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. MGuard(TM), InspireMDs Novel Coronary Stent System, was Celebrated by World Leading Interventional Cardiologists at the Transcatheter Cardiovascular Therapeutics (TCT) in Washington DC, USA, October 12-17 2008
2. InspireMD Announces Enrollment of First Patients in the MGuard(TM) Acute Myocardial Infarction Clinical Trial Data Will be Used to Confirm Initial Positive Results
3. Cephalon Announces Proposed Public Offering of Common Stock and Convertible Senior Subordinated Notes
4. Keryx Biopharmaceuticals Announces Appointment of Ron Bentsur as Chief Executive Officer
5. Martek to Announce Second Quarter 2009 Results
6. Aesthera Announces ANVISA Clearance to Market Photopneumatic Platforms in Brazil
7. The Hamner Institutes Announce Partnership With China Medical City
8. Oncothyreon announces commitments to purchase $11.1 million of company securities in a registered direct financing
9. Beckman Coulter, Inc. Announces Pricing of Common Stock Offering
10. MedClean Technologies, Inc. Announces Private Offer to Exchange Warrants
11. Angiotechs corporate partner, Boston Scientific, announces launch of third-generation TAXUS(R) Element(TM) Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... UTAH. (PRWEB) , ... May 25, 2016 , ... WEDI, ... healthcare information exchange, today announced that Charles W. Stellar has been named by the ... interim CEO since January 2016. As an executive leader with more than 35 years ...
(Date:5/24/2016)... La Jolla, CA (PRWEB) , ... May 24, 2016 , ... ... and financial planning for corporate executives and entrepreneurs, held The Future of San Diego ... leaders in the San Diego life science community attended the event with speakers Dr. ...
(Date:5/23/2016)... England , May 23, 2016 ... May 25 th at 10:15 a.m. ET before the ... the role genetically engineered mosquitos can play in controlling the ... carrier of the Zika virus.      (Logo: ... engineered male mosquito with a self-limiting gene. Trials in ...
(Date:5/20/2016)... ... May 20, 2016 , ... The leading Regenerative Veterinary ... most experienced veterinary clients have treated over 100 of their own patients with the ... provide the highest level of care for their patients. , The veterinarians are ...
Breaking Biology Technology:
(Date:3/31/2016)... 2016  Genomics firm Nabsys has completed a financial ... Bready , M.D., who returned to the company in ... leadership team, including Chief Technology Officer, John Oliver ... Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys from ...
(Date:3/21/2016)... -- Unique technology combines v ...   Xura, Inc. (NASDAQ: ... communications services, today announced it is working alongside SpeechPro ... particularly those in the Financial Services Sector, the ability ... a mobile app, alongside, and in combination with, traditional ...
(Date:3/14/2016)... NXTD ) ("NXT-ID" or the "Company"), ... the airing of a new series of commercials on Time ... 21 st .  The commercials will air on Bloomberg TV, ... the Street show. --> NXTD ) ("NXT-ID" or ... market, announces the airing of a new series of commercials ...
Breaking Biology News(10 mins):